Vogenx
VOGXVogenx is a clinical-stage biopharmaceutical company specializing in the discovery and development of novel therapies for serious metabolic dysfunctions.
Vogenx has filed an S-1 registration statement with the SEC and is not yet trading. Financial statements will appear here once it begins reporting as a public company.
S-1 Filings
Registration statements filed with the SEC ahead of the planned listing
Competitors
By market cap
By revenue growth
Profile
Vogenx is a clinical-stage biopharmaceutical company specializing in the discovery and development of novel therapies for serious metabolic dysfunctions. The company leverages its expertise in solute carrier biology to target glucose absorption and postprandial dysregulation. Its primary value proposition centers on advancing selective SGLT1 inhibitors to address significant unmet medical needs in endocrine and metabolic disorders.
A clinical-stage developer of a highly selective, minimally absorbed SGLT1 inhibitor with a unique site of action in the intestinal lumen.
Questions, answered.
- Who are Vogenx's competitors?
- Vogenx's key competitors include Amylyx Pharmaceuticals, MBX Biosciences, Vanda Pharmaceuticals, and others. These companies compete in similar markets and product categories.
- Who does Vogenx partner with?
- Vogenx's notable partners include Kissei Pharmaceutical Co., Ltd..
- Where is Vogenx headquartered?
- Vogenx is headquartered in United States of America.